Belinda E Kiely1, Andrew J Martin, Martin H N Tattersall, Anna K Nowak, David Goldstein, Nicholas R C Wilcken, David K Wyld, Ehtesham A Abdi, Amanda Glasgow, Philip J Beale, Michael Jefford, Paul A Glare, Martin R Stockler. 1. Belinda E. Kiely, Andrew J. Martin, and Martin R. Stockler, National Health and Medical Research Council Clinical Trials Centre, University of Sydney; Belinda E. Kiely, Martin H.N. Tattersall, Nicholas R.C. Wilcken, Philip J. Beale, and Martin R. Stockler, Sydney Medical School, University of Sydney; Belinda E. Kiely, Martin H.N. Tattersall, Philip J. Beale, and Martin R. Stockler, Sydney Cancer Centre-Royal Prince Alfred and Concord Hospitals, Sydney; David Goldstein, Prince of Wales Hospital Clinical School, University of New South Wales, Kensington; Nicholas R.C. Wilcken, Westmead Hospital, Westmead; Ehtesham A. Abdi, Tweed Hospital, Tweed Heads; Amanda Glasgow, Wollongong Hospital, Wollongong, New South Wales; Anna K. Nowak, School of Medicine and Pharmacology, University of Western Australia, Crawley; Anna K. Nowak, Sir Charles Gardner Hospital, Nedlands, Western Australia; David K. Wyld, Royal Brisbane and Women's Hospital, Brisbane, Queensland; Michael Jefford, Peter MacCallum Cancer Centre; Michael Jefford, University of Melbourne, Melbourne, Victoria, Australia; and Paul A. Glare, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: To determine the accuracy and usefulness of oncologists' estimates of survival time in individual patients with advanced cancer. PATIENTS AND METHODS: Twenty-one oncologists estimated the "median survival of a group of identical patients" for each of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with an observed survival time bounded by prespecified multiples of their estimated survival time. We expected 50% to live longer (or shorter) than their oncologist's estimate (calibration), 50% to live from half to double their estimate (typical scenario), 5% to 10% to live ≤ one quarter of their estimate (worst-case scenario), and 5% to 10% to live three or more times their estimate (best-case scenario). Estimates within 0.67 to 1.33 times observed survival were deemed precise. Discriminative value was assessed with Harrell's C-statistic and prognostic significance with proportional hazards regression. RESULTS: Median survival time was 11 months. Oncologists' estimates were relatively well-calibrated (61% shorter than observed), imprecise (29% from 0.67 to 1.33 times observed), and moderately discriminative (Harrell C-statistic 0.63; P = .001). The proportion of patients with an observed survival half to double their oncologist's estimate was 63%, ≤ one quarter of their oncologist's estimate was 6%, and three or more times their oncologist's estimate was 14%. Independent predictors of observed survival were oncologist's estimate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase more than 101 U/L (HR = 2.8; P = .0002), Karnofsky performance status ≤ 70 (HR = 2.3; P = .007), prostate primary (HR = 0.23; P = .002), and steroid use (HR = 2.4; P = .02). CONCLUSION: Oncologists' estimates of survival time were relatively well-calibrated, moderately discriminative, independently associated with observed survival, and a reasonable basis for estimating worst-case, typical, and best-case scenarios for survival.
PURPOSE: To determine the accuracy and usefulness of oncologists' estimates of survival time in individual patients with advanced cancer. PATIENTS AND METHODS: Twenty-one oncologists estimated the "median survival of a group of identical patients" for each of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with an observed survival time bounded by prespecified multiples of their estimated survival time. We expected 50% to live longer (or shorter) than their oncologist's estimate (calibration), 50% to live from half to double their estimate (typical scenario), 5% to 10% to live ≤ one quarter of their estimate (worst-case scenario), and 5% to 10% to live three or more times their estimate (best-case scenario). Estimates within 0.67 to 1.33 times observed survival were deemed precise. Discriminative value was assessed with Harrell's C-statistic and prognostic significance with proportional hazards regression. RESULTS: Median survival time was 11 months. Oncologists' estimates were relatively well-calibrated (61% shorter than observed), imprecise (29% from 0.67 to 1.33 times observed), and moderately discriminative (Harrell C-statistic 0.63; P = .001). The proportion of patients with an observed survival half to double their oncologist's estimate was 63%, ≤ one quarter of their oncologist's estimate was 6%, and three or more times their oncologist's estimate was 14%. Independent predictors of observed survival were oncologist's estimate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase more than 101 U/L (HR = 2.8; P = .0002), Karnofsky performance status ≤ 70 (HR = 2.3; P = .007), prostate primary (HR = 0.23; P = .002), and steroid use (HR = 2.4; P = .02). CONCLUSION: Oncologists' estimates of survival time were relatively well-calibrated, moderately discriminative, independently associated with observed survival, and a reasonable basis for estimating worst-case, typical, and best-case scenarios for survival.
Authors: Anuradha Vasista; Martin Stockler; Andrew Martin; Nick Pavlakis; Katrin Sjoquist; David Goldstein; Sanjeev Gill; Vikram Jain; Geoffrey Liu; George Kannourakis; Yeul Hong Kim; Louise Nott; Stephanie Snow; Matthew Burge; Dean Harris; Derek Jonker; Yu Jo Chua; Richard Epstein; Antony Bonaventura; Belinda Kiely Journal: Oncologist Date: 2019-04-01
Authors: Andrew S Epstein; Sophia E Kakarala; Valerie F Reyna; Ashish Saxena; Paul K Maciejewski; Manish A Shah; Holly G Prigerson Journal: J Pain Symptom Manage Date: 2020-11-27 Impact factor: 5.576
Authors: Stephanie Johnson; Josephine Clayton; Phyllis N Butow; William Silvester; Karen Detering; Jane Hall; Belinda E Kiely; Jonathon Cebon; Stephen Clarke; Melanie L Bell; Martin Stockler; Phillip Beale; Martin H N Tattersall Journal: BMJ Open Date: 2016-12-01 Impact factor: 2.692
Authors: Remko M van Eenennaam; Willeke J Kruithof; Michael A van Es; Esther T Kruitwagen-van Reenen; Henk-Jan Westeneng; Johanna M A Visser-Meily; Leonard H van den Berg; Anita Beelen Journal: BMC Neurol Date: 2020-12-14 Impact factor: 2.474
Authors: Yu Jung Kim; Seok Joon Yoon; Sang-Yeon Suh; Yusuke Hiratsuka; Beodeul Kang; Si Won Lee; Hong-Yup Ahn; Koung Jin Suh; Ji-Won Kim; Se Hyun Kim; Jin Won Kim; Keun-Wook Lee; Jee Hyun Kim; Jong Seok Lee Journal: PLoS One Date: 2022-04-21 Impact factor: 3.240
Authors: Sharon H Nahm; Martin R Stockler; Andrew J Martin; Peter Grimison; Peter Fox; Rob Zielinski; Geoffrey At Hawson; Martin Hn Tattersall; Belinda E Kiely Journal: Support Care Cancer Date: 2022-06-15 Impact factor: 3.359